Mersana Therapeutics Inc (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages
Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $8.33.
Several equities analysts recently weighed in on MRSN shares. ValuEngine cut Mersana Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 21st. Zacks Investment Research raised Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 ...